Use of response surface methods and path of steepest ascent to optimize ligand-binding assay sensitivity

被引:25
|
作者
Joyce, Alison P. [1 ]
Leung, Sheldon S. [1 ]
机构
[1] Pfizer Inc, Andover, MA 01810 USA
关键词
Ligand-binding assay (LBA); Response surface methods (RSM); Steepest ascent; Design of Experiments (DOE); Assay optimization; Signal to Noise Ratio (SNR); INTERFERENCE; ELISA;
D O I
10.1016/j.jim.2013.02.019
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Response surface methods (RSM) combined with a steepest ascent approach is a powerful technique to optimize assay performance. In this case, a ligand-binding assay (LEA) to quantitate a peptide biotherapeutic was optimized for improved sensitivity using this technique. Conditions were elucidated to enable pg/mL quantitation of the peptide in human plasma using steepest ascent to efficiently optimize assay factors. Instead of relying solely on assay development experience and intuition to improve assay sensitivity, this systematic approach takes advantage of a predictive mathematical model generated through response surface methods that defines a specific path towards greater predicted assay sensitivity. The actual response observed along the steepest ascent path was in good agreement with the model for several steps, until reagent concentrations moved beyond the physical limits of the system, and model breakdown occurred. RSM combined with steepest ascent method proved a useful tool for sensitivity optimization in three ways: (1) The required LBA sensitivity performance (approximately 200 pg/mL), measured as a signal-to-noise ratio (SNR) at the targeted lower limit of quantitation (LLOQ), was efficiently achieved in only two optimization experiments; (2) Steepest ascent confirmed that the desired sensitivity was found within the initial RSM design space, and no further gain in sensitivity was found venturing beyond this design space along the steepest ascent path; (3) The desired assay sensitivity was maintained over a reasonable range of reagent concentrations along the steepest ascent path, indicating assay robustness for this parameter. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:12 / 23
页数:12
相关论文
共 14 条
  • [1] Inequalities for the precision of the path of steepest ascent in response surface methodology
    Sztendur, EM
    Diamond, NT
    [J]. INEQUALITY THEORY AND APPLICATIONS, VOL 1, 2001, : 295 - 301
  • [2] SIMPLE GRAPHICAL METHODS FOR USE WITH COMPLEX LIGAND-BINDING AND ENZYME MECHANISMS
    CRABBE, MJC
    [J]. FEBS LETTERS, 1988, 235 (1-2): : 183 - 188
  • [3] Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics
    Duo, Jia
    Bruno, JoAnne
    Kozhich, Alexander
    David-brown, Donata
    Luo, Linlin
    Kwok, Suk
    Santockyte, Rasa
    Haulenbeek, Jonathan
    Liu, Rong
    Hamuro, Lora
    Peterson, Jon E.
    Piccoli, Steven
    DeSilva, Binodh
    Pillutla, Renuka
    Zhang, Yan J.
    [J]. BIOANALYSIS, 2018, 10 (08) : 559 - 576
  • [4] Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug
    Staack, Roland F.
    Jordan, Gregor
    Viert, Maria
    Schaefer, Martin
    Papadimitriou, Apollon
    Heinrich, Julia
    [J]. BIOANALYSIS, 2015, 7 (24) : 3097 - 3106
  • [5] TEGUMENTAL SURFACE MODULATION IN SCHISTOSOMA-MANSONI PRIMARY SPOROCYSTS IN RESPONSE TO LIGAND-BINDING
    DUNN, TS
    YOSHINO, TP
    [J]. PARASITE IMMUNOLOGY, 1991, 13 (02) : 121 - 135
  • [6] Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons
    Tu, Jing
    Bennett, Patrick
    [J]. BIOANALYSIS, 2017, 9 (14) : 1107 - 1122
  • [7] Implementing a tiered approach to bioanalytical method validation for large-molecule ligand-binding assay methods in pharmacokinetic assessments
    Watson, Rebecca G.
    Clements-Egan, Adrienne
    Schantz, Allen
    Ware, Mark
    Wu, Bonnie
    Yang, Tong-Yuan
    Shankar, Gopi
    Marini, Joseph C.
    [J]. BIOANALYSIS, 2017, 9 (18) : 1407 - 1422
  • [8] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481
  • [9] Ligand-binding domain of farnesoid X receptor (FXR) had the highest sensitivity and activity among FXR variants in a fluorescence-based assay
    Cho, KH
    Park, JY
    Han, JI
    Jeong, TS
    [J]. LIPIDS, 2003, 38 (11) : 1149 - 1156
  • [10] COMPUTER-SIMULATIONS APPLIED TO SITE SPECIFIC MUTAGENESIS AND LIGAND-BINDING - THE USE OF FREE-ENERGY PERTURBATION-METHODS
    KOLLMAN, P
    [J]. ADVANCES IN PROTEIN DESIGN : INTERNATIONAL WORKSHOP 1988, 1989, 12 : 57 - 64